Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.05 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 2 pathways; mostly vesicle traffic | 1.00 |
No case: the score is under the bar. Receipt 5215
Sealed predictions
- SBF2 in dopamine neurons, braak+0.15 (p 0.706) → +0.88 (p 0.002)receipt 5223
Swarm cases
receipt 5223: SBF2 in dopamine neurons, braak
- power
- full sample +0.54 (p 0.020, n 18), 95% CI +0.10 to +0.81. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: +0.47 (p 0.050, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.52 (p 0.028, n 18). not the mix.
- skeptic
- leave-one-out range +0.48 to +0.76, sign flips 0; without severely affected donors +0.54 (p 0.020, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SBF2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts